secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0000950170-24-011011
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani announces positive Phase 1 topline results for oral ustekinumab biosimilar RT-111
--------------------------------------------------------------------------------

- RT-111 achieved 84% bioavailability vs subcutaneous Stelara injection; higher Cmax and shorter Tmax observed.
- No serious adverse events; mild transient AEs resolved without intervention; no participants withdrew.
- Celltrion holds right of first negotiation to acquire worldwide rights to RT-111 after successful Phase 1.
- This marks Rani's third successful Phase 1 trial using RaniPill technology; potential differentiated oral dosing for psoriasis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024011011/0000950170-24-011011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024011011/rani-20240205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-011011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer